Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00476294 · ClinicalTrials.gov registry record

Long-Term Follow Up Study for AMD3100 Patients

A clinical trial, sponsored by M.D. Anderson Cancer Center.

Completed
Registry status
7
Enrollment target

NCT00476294: Completed study, sponsored by M.D. Anderson Cancer Center.

NCT00476294 is a clinical trial that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00476294 has completed, sponsored by M.D. Anderson Cancer Center.

COMPLETED
Registry status
7 participants
Enrollment target

Study Summary

Objectives: The objective of this long-term observational study is to assess progression-free survival and overall survival for a period of five years following the first dose of study treatment (placebo or plerixafor \[AMD3100\]) in protocol AMD3100-3102. Patients that received at least 1 dose of study treatment (placebo or plerixafor) in the multicenter, randomized, double-blind, placebo-controlled AMD3100-3102 study, which was designed to evaluate plerixafor plus granulocyte colony stimulating factor (G-CSF) versus placebo plus G-CSF to mobilize hematopoietic stem cells for autologous transplantation of Multiple Myeloma (MM) patients are eligible.

Interventions

  • OTHER Telephone Questionnaire

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2006-10
Est. Completion 2012-07

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT00476294

The ClinicalTrials.gov registry entry for NCT00476294 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Telephone Questionnaire is the first listed.

NCT00476294 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00476294 about?

NCT00476294 is a clinical study titled "Long-Term Follow Up Study for AMD3100 Patients". Objectives: The objective of this long-term observational study is to assess progression-free survival and overall survival for a period of five years following the first dose of study treatment (placebo or plerixafor \[AMD3100\]) in protocol AMD3100-3102. Patients that received at least 1 dose of ...

What is the current status of trial NCT00476294?

This trial is currently completed. The enrollment target is 7 participants. The study started on 2006-10. Estimated completion is 2012-07.

What interventions are being tested in trial NCT00476294?

The interventions under investigation include: Telephone Questionnaire (OTHER).

Who is sponsoring clinical trial NCT00476294?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.